SEATTLE (Map) - In the news release, Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results, issued earlier today by Cell Therapeutics, Inc. over PR Newswire, we are advised by the company that the release contained additional tabular material, originally issued inadvertently without the material. The additional tabular material follows:

Cell Therapeutics, Inc. Consolidated Statements of Operations (In thousands, except for per share amounts) (Unaudited) Three Months Ended Year Ended December 31, December 31, 2007 2006 2007 2006 Revenues: Product sales 47 - 47 - License and contract revenue 20 20 80 80 Total revenues 67 20 127 80 Operating expenses: Cost of product sold 49 - 49 - Research and development 21,651 16,623 72,019 61,994 Selling, general and administrative 10,923 8,075 35,517 35,894 Acquired in-process research and development 3,272 - 24,615 - Amortization of purchased intangibles 275 204 913 792 Total operating expenses 36,170 24,902 133,113 98,680 Loss from operations (36,103) (24,882) (132,986) (98,600) Other income (expense): Investment and other income 363 1,023 2,430 2,866 Interest expense (2,460) (2,941) (12,517) (19,829) Foreign exchange gain 1,515 880 4,657 1,877 Make-whole interest expense - - (2,310) (24,753) Gain on derivative liabilities 54 820 3,672 6,024 Gain (loss) on exchange of convertible notes (972) - (972) 7,978 Settlement expense - (10,499) (160) (11,382) Net loss before minority interest (37,603) (35,599) (138,186) (135,819) Minority interest in net loss of subsidiary 42 - 78 - Net loss (37,561) (35,599) (138,108) (135,819) Preferred stock beneficial conversion feature (1,248) - (9,549) - Preferred stock dividends (253) - (648) - Net loss attributable to common shareholders $(39,062) $(35,599) $(148,305) $(135,819) Basic and diluted net loss per common share $(0.74) $(1.00) $(3.27) $(4.84) Shares used in calculation of basic and diluted net loss per common share (1) 52,469 35,601 45,292 28,070 Balance Sheet Data: (amounts in thousands) December 31, 2007 2006 Cash and cash equivalents, securities (unaudited) available-for-sale and interest receivable $18,392 $54,407 Working capital (30,909) 30,166 Total assets 73,513 101,821 Convertible debt 137,396 166,178 Accumulated deficit (1,109,413) (961,108) Shareholders' deficit (134,125) (101,604) (1) Amounts reflect a one-for-four reverse stock split of our common stock effective April 15, 2007.

------

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results

Restructured majority of convertible notes due June 2008
Reduced net operating expenses going forward
Projects Zevalin(R) net sales revenues of $15 million in 2008

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Seattle-Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today reported recent accomplishments and financial results for the quarter and twelve months ended December 31, 2007.

Recent Events

Announced completion of Zevalin(R) (Ibritumomab Tiuxetan) acquisition from Biogen Idec for an upfront payment of $10.1 million and initiated building Zevalin sales, marketing, and medical affairs infrastructure

Raised $14.8 million in aggregate gross proceeds through the issuance of common and preferred stock and warrants; raised $51.7 million in an offering of 9% Senior Convertible Notes due 2012; of which $16.2 million was used to induce the conversion of $21.5 million of outstanding Series A,B,C, and D convertible preferred securities to common stock

Restructured approximately 81 percent of the convertible notes due in June 2008, reducing total due in 2008 from $55.9 million to $10.7 million

Reduced expected net operating expenses by 35%, targeting $77 million in net cash operating expenses in 2008, by focusing resources on reaching $15 million in net Zevalin revenues, pursuing European marketing authorization (MAA) for XYOTAX (paclitaxel poliglumex, CT-2103), preparing for a potential U.S. marketing application (NDA) for pixantrone (BBR 2778) in 2009, and supporting the advancement of brostallicin

"Now that we have made significant progress on our strategy of simplifying our capital structure, reducing operating expenses, and shifting our resources to near-term opportunities, we believe we are in a much stronger position to increase revenues, execute our late-stage clinical programs, and create value for our shareholders and patients," said James A. Bianco, M.D., President and CEO of CTI. "With our financial restructuring and strategic realignment completed, we can focus on commercializing Zevalin and developing our late- stage product pipeline."

Financial Results

For the quarter ended December 31, 2007, CTI reported a net loss attributable to common shareholders of $39.1 million ($0.74 per share) compared to a net loss attributable to common shareholders of $35.6 million ($1.00 per share) for the same period in 2006.

For the year ended December 31, 2007, CTI posted a net loss attributable to common shareholders of $148.3 million ($3.27 per share), which includes $24.6 million in acquired in-process research and development expense associated with the acquisitions of Systems Medicine and Zevalin. The acquired in-process research and development charge is primarily a non-cash expense. This compares to a net loss attributable to common shareholders of $135.8 million ($4.84 per share) for the same period in 2006. In 2007, CTI recorded make-whole interest expense of $2.3 million compared to $24.8 million in 2006, which was primarily related to conversions of our 6 3/4% convertible notes during 2006.

The Company ended the year with cash and cash equivalents, securities available-for-sale and interest receivable of approximately $18.4 million. In January 2008, CTI sold shares to Societe Generale, pursuant to the Step-Up Equity Financing Agreement, for gross proceeds of approximately $1.27 million. In March 2008, CTI raised approximately $35.5 million in gross proceeds from the sale of convertible senior notes after taking into consideration $16.2 million paid as a conversion inducement to preferred securities holders, which eliminated $21.5 million of redeemable preferred stock.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin, reducing net operating expenses in 2008, and the development of XYOTAX, pixantrone, and brostallicin, which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX, pixantrone, and brostallicin in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, XYOTAX, pixantrone, and brostallicin, the Company's ability to continue to raise capital as needed to fund its operations, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10- K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: media@ctiseattle.com http://www.cticseattle.com/media.htm Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: invest@ctiseattle.com http://www.cticseattle.com/investors.htm